Drugs / CGB3002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07660341 | Jun 2026 → Apr 2027 expected | Alzheimer disease | ChainGen Biopharma Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CGB3002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07660341 ↗ |
| Route | Intravenous | “single intravenous dose of CGB3002” NCT07660341 ↗ |